Movement Alert｜InnoCare Pharma Rises 5.09% in Regular Trading, Biotech Sector Rallies as CDH17 ADC Clinical Data Published

Market Focus07-15

On July 15, InnoCare Pharma rose 5.09% in regular trading, trading at HK$15.04 per share, with turnover of HK$67.34 million.

The gain was driven by a broad-based rally in the biotech sector alongside company-specific catalysts. On the sector front, SKB Bio rose 10.2%, Akeso rose 7.98%, Innovent Bio rose 7.66%, 3SBio rose 6.56%, and BeiGene rose 2.37%. At the company level, InnoCare's self-developed CDH17-targeting ADC drug ICP-B208 completed first patient dosing, with clinical data recently published in an international academic journal. ICP-B208 is a novel ADC utilizing a proprietary technology platform, and no CDH17-targeted ADC has yet been approved globally. Additionally, 2,044,750 new shares from the company's 2023 restricted stock incentive plan became listed for trading today, following completion of share registration for the third vesting period of initial grants and second vesting period of reserved grants.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1137000476?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-07-15 09:57","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1137000476","market":"hk","top_or_hot":-1,"title":"Movement Alert｜InnoCare Pharma Rises 5.09% in Regular Trading, Biotech Sector Rallies as CDH17 ADC Clinical Data Published","media":"Market Focus","content":"<p><p>On July 15, InnoCare Pharma rose 5.09% in regular trading, trading at HK$15.04 per share, with turnover of HK$67.34 million.</p><p>The gain was driven by a broad-based rally in the biotech sector alongside company-specific catalysts. On the sector front, SKB Bio rose 10.2%, Akeso rose 7.98%, Innovent Bio rose 7.66%, 3SBio rose 6.56%, and BeiGene rose 2.37%. At the company level, InnoCare's self-developed CDH17-targeting ADC drug ICP-B208 completed first patient dosing, with clinical data recently published in an international academic journal. ICP-B208 is a novel ADC utilizing a proprietary technology platform, and no CDH17-targeted ADC has yet been approved globally. Additionally, 2,044,750 new shares from the company's 2023 restricted stock incentive plan became listed for trading today, following completion of share registration for the third vesting period of initial grants and second vesting period of reserved grants.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜InnoCare Pharma Rises 5.09% in Regular Trading, Biotech Sector Rallies as CDH17 ADC Clinical Data Published</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜InnoCare Pharma Rises 5.09% in Regular Trading, Biotech Sector Rallies as CDH17 ADC Clinical Data Published\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-07-15 09:57</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On July 15, InnoCare Pharma rose 5.09% in regular trading, trading at HK$15.04 per share, with turnover of HK$67.34 million.</p><p>The gain was driven by a broad-based rally in the biotech sector alongside company-specific catalysts. On the sector front, SKB Bio rose 10.2%, Akeso rose 7.98%, Innovent Bio rose 7.66%, 3SBio rose 6.56%, and BeiGene rose 2.37%. At the company level, InnoCare's self-developed CDH17-targeting ADC drug ICP-B208 completed first patient dosing, with clinical data recently published in an international academic journal. ICP-B208 is a novel ADC utilizing a proprietary technology platform, and no CDH17-targeted ADC has yet been approved globally. Additionally, 2,044,750 new shares from the company's 2023 restricted stock incentive plan became listed for trading today, following completion of share registration for the third vesting period of initial grants and second vesting period of reserved grants.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"09969","symbol_name":"诺诚健华","start_time":0,"source_url":"","article_id":"1137000476","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1137000476","pubTimestamp":1784080661,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On July 15, InnoCare Pharma rose 5.09% in regular trading, trading at HK$15.04 per share, with turnover of HK$67.34 million.The gain was driven by a broad-based rally in the biotech sector alongside...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"09969":"诺诚健华"},"translate_title":"走势提醒|CDH17 ADC临床数据公布，诺诚健华常规交易上涨5.09%，生物技术板块上涨","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"09969":1},"content_text":"On July 15, InnoCare Pharma rose 5.09% in regular trading, trading at HK$15.04 per share, with turnover of HK$67.34 million.The gain was driven by a broad-based rally in the biotech sector alongside company-specific catalysts. On the sector front, SKB Bio rose 10.2%, Akeso rose 7.98%, Innovent Bio rose 7.66%, 3SBio rose 6.56%, and BeiGene rose 2.37%. At the company level, InnoCare's self-developed CDH17-targeting ADC drug ICP-B208 completed first patient dosing, with clinical data recently published in an international academic journal. ICP-B208 is a novel ADC utilizing a proprietary technology platform, and no CDH17-targeted ADC has yet been approved globally. Additionally, 2,044,750 new shares from the company's 2023 restricted stock incentive plan became listed for trading today, following completion of share registration for the third vesting period of initial grants and second vesting period of reserved grants.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.46.0","shortVersion":"4.46.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1137000476","isCrawlerRequest":true}